SCHEMBL3493323

SCHEMBL3493323

COC(=O)c1ncn(CC(O)c2ccccc2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.43
ALDH1A1 P00352 6/20 0.42
MAPT P10636 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPK1 P28482 2/20 0.40
HSD17B10 Q99714 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 1/20 0.40
APAF1 O14727 1/20 0.40
CYP2D6 P10635 1/20 0.39
PTGS2 P35354 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495526 0.86 ALDH1A1 (0.40) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL3491785 0.86 PKM (0.47) PKMALDH1A1MAPTCYP3A4CYP2C9
SCHEMBL5795140 0.78 KDM4E (0.46) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL3496351 0.77 MAPK1 (0.55) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL3494712 0.77 MAPK1 (0.55) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL15358486 0.76 PTGS2 (0.57) PKMALDH1A1NPSR1SMN1; SMN2KDM4E
SCHEMBL3495492 0.76 MAPK1 (0.43) ALDH1A1MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL3491885 0.72 TSHR (0.43) PKMALDH1A1MAPTKDM4EMAPK1
SCHEMBL4638859 0.71 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2KDM4ECYP2D6
SCHEMBL4150358 0.68 PKM (0.74) PKMALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 PKM 1279/4885ALDH1A1 1062/4885MAPT 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.